All In MedTech

Device Trial Radar · NCT07560046

Combating Related Epidemics in HCV

Combating Related Epidemics in HCV Through Simplified Testing and Treatment. A Cluster Randomized Trial of Point-of-care Hepatitis C Testing and Treatment Among Key Populations

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,280 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,280

Planned (sponsor's estimate)

Start

Jan 20, 2027

Primary completion

Nov 30, 2029

Study completion Jul 31, 2030

Sponsor

Lead sponsor
Duke UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Yale University; West Virginia University; University of San Diego; Cepheid; Gilead Sciences; National Institute of Allergy and Infectious Diseases (NIAID); Flinders University International Centre for Point-of-care Testing; Kirby Institute; bioLytical Laboratories
First posted
Apr 30, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-arm cluster randomized control trial to evaluate the effectiveness of a single-visit point-of-care (POC) test and treat bundle (intervention arm) compared to the current standard-of-care (SOC, control arm). 1:1 randomization occurs at the site level.

Conditions

  • HIV - Human Immunodeficiency Virus
  • Hepatitis B Virus (HBV)
  • HEPATITIS C (HCV)

Interventions

  • Cepheid GeneXpert HCV TestDevice

    Cepheid Xpert HCV Test, performed on the GeneXpert Xpress system, in an automated in vitro reverse transcription polymerase chain reaction (RT-PCR) test for the qualitative detection of Hep C (HCV) RNA in human fingerstick.

  • INSTI HIV - 1/2 AntibodyDiagnostic test

    The bioLytical Laboratories INSTI HIV-1/HIV-2 Antibody test is a single-use rapid assay for the detection of antibodies to HIV-1/HIV-2. This test is conducted from a fingerstick using whole blood.

  • bioLytical Laboratories iStatis Hepatitis B Surface Antigen TestDiagnostic test

    The iStatis Hepatitis B Surface Antigen test is a single use, rapid, lateral flow, in vitro qualitative immunoassay for the detection of Hepatitis B Surface Antigen in human EDTA-whole blood, fingerstick whole blood, serum, or plasma.

  • Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]Drug

    Participants with detectable HCV RNA on Xpert test will receive sofosbuvir/velpatasvir at the same visit as the POC test in the intervention arm. Participants in the SOC arm will receive sofosbuvir/velpatasvir after standard of care testing and treatment assessment has been completed.

  • Sofosbuvir/Velpatasvir/VoxilaprevirDrug

    Sofosbuvir/Velpatasvir/Voxilaprevir will be provided to participants who experience a relapse of HCV, re-infection, or virologic failure based on point-of-care (POC) or standard of care (SOC) testing after completion of sofosbuvir/velpatasvir as part of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who complete the Hepatitis C Virus (HCV) care cascade within 24 weeks of study entry in intervention versus Standard of Care (SOC) arm.Time frame: 24 weeks from study enrollment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.